Trial · NCT03663582
Results by group31
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 31
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET) | Teduglutide | -2.92 | Standard Deviation 3.463 | Liter per week (L/Week) | |
| Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET) | Teduglutide | -22.19 | Standard Deviation 24.953 | Percent change | |
| Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 20 | Teduglutide | 66.7 | Percentage of participants | ||
| Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 24 | Teduglutide | 66.7 | Percentage of participants | ||
| Percentage of Participants Who Achieved at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) at End of Treatment/Early Termination (EOT/ET) | Teduglutide | 57.1 | Percentage of participants | ||
| Change From Baseline in Days Per Week of Parenteral Support (PS) at End of Treatment/Early Termination (EOT/ET) | Teduglutide | -0.43 | Standard Deviation 1.134 | Days per Week | |
| Change From Baseline in Plasma Citrulline Levels at End of Treatment/Early Termination (EOT/ET) | Teduglutide | 11.973 | Standard Deviation 11.7309 | Micromoles (mcmol) | |
| Number of Participants Who Were Completely Weaned Off Parenteral Support (PS) at Week 24/End of Treatment (EOT) | Teduglutide | Weaned Off Parenteral Support: No | 7 | Participants | |
| Number of Participants Who Were Completely Weaned Off Parenteral Support (PS) at Week 24/End of Treatment (EOT) | Teduglutide | Weaned Off Parenteral Support: Yes | 0 | Participants | |
| Area Under the Plasma Concentration-Time Curve From Zero to the Last Measurable Concentration (AUC0-t) of Teduglutide | Teduglutide | 240.3 | Standard Deviation 80.651 | Hour*nanogram per milliliter (h*ng/mL) | |
| Maximum Plasma Concentration (Cmax) of Teduglutide | Teduglutide | 49.50 | Standard Deviation 16.427 | Nanograms per milliliter (ng/mL) | |
| Time to Maximum Plasma Concentration (Tmax) of Teduglutide | Teduglutide | 3.00 | Full Range 1.87 to 5.92 | Hour | |
| Terminal-phase Half-life (T1/2) of Teduglutide | Teduglutide | 1.09 | Full Range 0.751 to 1.30 | Hour | |
| Apparent Clearance (CL/F) of Teduglutide | Teduglutide | 10858.9 | Standard Deviation 4038.5 | Milliliter per hour (mL/h) | |
| Apparent Volume of Distribution (Vz/F) of Teduglutide | Teduglutide | 17167.4 | Standard Deviation 8371.9 | Milliliter (mL) | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Teduglutide | 7 | Participants | ||
| Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG) | Teduglutide | 0 | Participants | ||
| Change From Baseline in Blood Pressure at End of Treatment/Early Termination (EOT/ET) | Teduglutide | Systolic Blood Pressure: EOT (up to Week 28) | 2.4 | Standard Deviation 19.37 | Millimetre of mercury (mmHg) |
| Change From Baseline in Blood Pressure at End of Treatment/Early Termination (EOT/ET) | Teduglutide | Diastolic Blood Pressure: EOT (up to Week 28) | 6.6 | Standard Deviation 20.59 | Millimetre of mercury (mmHg) |
| Change From Baseline in Pulse Rate at End of Treatment/Early Termination (EOT/ET) | Teduglutide | 2.6 | Standard Deviation 9.88 | Beats per minute (beats/min) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03663582/results